Published in Cancer Weekly, September 20th, 2005
Study 1: Hepatocyte growth factor sheds light on acute myeloid leukemia and survival.
According to a study from South Korea, "the present study evaluated the serum levels of known angiogenic factors and analyzed their prognostic significance in patients with acute or chronic leukemia."
"Enzyme-linked immunosorbent assays (ELISAs) were performed to quantify the basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), tumor necrosis factor-alpha (TNF-alpha), angiogenin, and matrix...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.